Literature DB >> 17210710

Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.

Shehla Pervin1, Rajan Singh, Estebes Hernandez, Guoyao Wu, Gautam Chaudhuri.   

Abstract

Nitric oxide (NO) in nanomolar (nmol/L) concentrations is consistently detected in tumor microenvironment and has been found to promote tumorigenesis. The mechanism by which NO enhances tumor progression is largely unknown. In this study, we investigated the possible mechanisms and identified cellular targets by which NO increases proliferation of human breast cancer cell lines MDA-MB-231 and MCF-7. DETA-NONOate, a long acting NO donor, with a half-life of 20 h, was used. We found that NO (nmol/L) dramatically increased total protein synthesis in MDA-MB-231 and MCF-7 and also increased cell proliferation. NO specifically increased the translation of cyclin D1 and ornithine decarboxylase (ODC) without altering their mRNA levels or half-lives. Critical components in the translational machinery, such as phosphorylated mammalian target of rapamycin (mTOR) and its downstream targets, phosphorylated eukaryotic translation initiation factor and p70 S6 kinase, were up-regulated following NO treatment, and inhibition of mTOR with rapamycin attenuated NO induced increase of cyclin D1 and ODC. Activation of translational machinery was mediated by NO-induced up-regulation of the Raf/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase/ERK (Raf/MEK/ERK) and phosphatidylinositol 3-kinase (PI-3 kinase)/Akt signaling pathways. Up-regulation of the Raf/MEK/ERK and PI-3 kinase/Akt pathways by NO was found to be mediated by activation of Ras, which was cyclic guanosine 3',5'-monophosphate independent. Furthermore, inactivation of Ras by farnesyl transferase inhibitor or K-Ras small interfering RNA attenuated NO-induced increase in proliferation signaling and cyclin D1 and ODC translation, further confirming the involvement of Ras activation during NO-induced cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210710     DOI: 10.1158/0008-5472.CAN-05-4623

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.

Authors:  Sharon A Glynn; Brenda J Boersma; Tiffany H Dorsey; Ming Yi; Harris G Yfantis; Lisa A Ridnour; Damali N Martin; Christopher H Switzer; Robert S Hudson; David A Wink; Dong H Lee; Robert M Stephens; Stefan Ambs
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

2.  NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.

Authors:  Hirokazu Okayama; Motonobu Saito; Naohide Oue; Jonathan M Weiss; Jimmy Stauffer; Seiichi Takenoshita; Robert H Wiltrout; S Perwez Hussain; Curtis C Harris
Journal:  Int J Cancer       Date:  2012-06-13       Impact factor: 7.396

3.  Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.

Authors:  Esther Lopez-Rivera; Padmini Jayaraman; Falguni Parikh; Michael A Davies; Suhendan Ekmekcioglu; Sudeh Izadmehr; Denái R Milton; Jerry E Chipuk; Elizabeth A Grimm; Yeriel Estrada; Julio Aguirre-Ghiso; Andrew G Sikora
Journal:  Cancer Res       Date:  2014-01-07       Impact factor: 12.701

Review 4.  Nitric oxide release: part III. Measurement and reporting.

Authors:  Peter N Coneski; Mark H Schoenfisch
Journal:  Chem Soc Rev       Date:  2012-02-24       Impact factor: 54.564

5.  Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.

Authors:  Andrew G Sikora; Alexander Gelbard; Michael A Davies; Daisuke Sano; Suhendan Ekmekcioglu; John Kwon; Yared Hailemichael; Padmini Jayaraman; Jeffrey N Myers; Elizabeth A Grimm; Willem W Overwijk
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 6.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

7.  Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.

Authors:  Kalpana Mujoo; Vladislav G Sharin; Emil Martin; Byung-Kwon Choi; Courtney Sloan; Lubov E Nikonoff; Alexander Y Kots; Ferid Murad
Journal:  Nitric Oxide       Date:  2009-12-03       Impact factor: 4.427

Review 8.  iNOS: a potential therapeutic target for malignant glioma.

Authors:  A Jahani-Asl; A Bonni
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

9.  Molecular mechanisms for discrete nitric oxide levels in cancer.

Authors:  Lisa A Ridnour; Douglas D Thomas; Christopher Switzer; Wilmarie Flores-Santana; Jeffrey S Isenberg; Stefan Ambs; David D Roberts; David A Wink
Journal:  Nitric Oxide       Date:  2008-04-22       Impact factor: 4.427

10.  Short-period hypoxia increases mouse embryonic stem cell proliferation through cooperation of arachidonic acid and PI3K/Akt signalling pathways.

Authors:  S H Lee; M Y Lee; H J Han
Journal:  Cell Prolif       Date:  2008-04       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.